Ensysce Biosciences, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2018 | $-216.8K | $-216.8K | — | — |
| Jun 2018 | $-452.1K | $-452.1K | — | — |
| Sep 2018 | $-110.7K | $-110.7K | — | — |
| Dec 2018 | $-458.6K | $-458.6K | — | — |
| Mar 2019 | $-294.4K | $-294.4K | — | — |
| Jun 2019 | $-432.4K | $-432.4K | — | — |
| Sep 2019 | $-272.2K | $-272.2K | — | — |
| Dec 2019 | $-425.8K | $-425.8K | — | — |
| Mar 2020 | $-234.4K | $-234.4K | — | — |
| Jun 2020 | $-326.2K | $-326.2K | — | — |
| Sep 2020 | $-152.9K | $-152.9K | — | — |
| Dec 2020 | $-533.9K | $-533.9K | — | — |
| Mar 2021 | $-517.1K | $-517.1K | — | $43.8K |
| Jun 2021 | $-132.3K | $-132.3K | — | $36.4K |
| Sep 2021 | $-3.8M | $-3.8M | — | $24.8K |
| Dec 2021 | $-3.8M | $-3.8M | — | $16.7K |
| Mar 2022 | $-3.4M | $-3.4M | — | $402.4K |
| Jun 2022 | $-4.4M | $-4.4M | — | $295.6K |
| Sep 2022 | $-6.7M | $-6.7M | — | $157.1K |
| Dec 2022 | $-3.3M | $-3.3M | — | $216.7K |
| Mar 2023 | $-3.6M | $-3.6M | — | $117.1K |
| Jun 2023 | $-3.1M | $-3.1M | — | $77.4K |
| Sep 2023 | $-2.3M | $-2.3M | — | $55.7K |
| Dec 2023 | $-1.8M | $-1.8M | — | $628.9K |
| Mar 2024 | $-3.4M | $-3.4M | — | $33.2K |
| Jun 2024 | $-2.3M | $-2.3M | — | $26.5K |
| Sep 2024 | $-1.0M | $-1.0M | — | $20.8K |
| Dec 2024 | $-764.1K | $-764.1K | — | $30.1K |
| Mar 2025 | $-1.7M | $-1.7M | — | $16.3K |
| Jun 2025 | $-2.7M | $-2.7M | — | $186.8K |
| Sep 2025 | $-1.9M | $-1.9M | — | $-50.3K |
| Dec 2025 | $-1.5M | $-1.5M | — | $24.3K |
| Mar 2026 | $-3.5M | $-3.5M | — | $8.7K |
| Jun 2026 | $-2.0M | $-2.0M | — | $1.9K |